01 January 2008
Siemens Healthcare Diagnostics immunosuppressive drug monitoring solutions
T. Wei, N. Morjana, S. Goss, L. Bantum, Y. Yue, R. Janzen, G. SiefringAnn Transplant 2008; 13(1): 37-37 :: ID: 880196
Abstract
Siemens Healthcare Diagnostics offers comprehensive and flexible solutions for Immunosuppressive Drug Monitoring, designed to meet the needs of our diverse worldwide customer base. Our innovative Dimension® clinical chemistry system (DM) provides a full menu of the only onboard pretreatment whole blood methods available. These methods are easily integrated into the central laboratory - whether you are a large transplantation center, or a small community hospital. The Syva® ISD products have been available since the early 1990's and have been in use in numerous laboratories worldwide. These methods employ the Emit® technology and allow the customer to choose the system that best suits their testing volume needs. The performance is summarized below.
Keywords: cutaneous abscess, osteomylitis, bladder tissue, electrical impedance, first record-able reading, optimal probe pressure
In Press
Original article
Four Years of Clinical Experience With COVID-19 Outcomes in Heart Transplant RecipientsAnn Transplant In Press; DOI: 10.12659/AOT.952888
Original article
Determinants of Lack of Consent for Deceased Organ Donation Among Nurses and Physicians: A Cross-Sectional ...Ann Transplant In Press; DOI: 10.12659/AOT.953598
Original article
Influence of Pretransplant and Posttransplant Diabetes on Long-Term Heart Transplant OutcomesAnn Transplant In Press; DOI: 10.12659/AOT.953220
Original article
Learning Curve and Outcomes of Pure Laparoscopic Donor Major Hepatectomy Performed by Fellowship-Trained Su...Ann Transplant In Press; DOI: 10.12659/AOT.953061
Most Viewed Current Articles
24 Aug 2021 : Review article 21,439
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article 17,693
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
22 Nov 2022 : Original article 16,494
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
05 Apr 2022 : Original article 16,401
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604






